Hyperuricaemia treatment in acute heart failure patients does
not improve their long-term prognosis: a propensity score
matched analysis from the AHEAD registry

a 2019

Hyperuricaemia treatment in acute heart failure patients does not improve their long-term prognosis: a propensity score matched analysis from the AHEAD registry

MIKLÍKOVÁ, Marie, Jiří JARKOVSKÝ, Klára BENEŠOVÁ, Roman MIKLÍK, Marián FELŠŐCI et. al.

Základní údaje

Originální název

Hyperuricaemia treatment in acute heart failure patients does not improve their long-term prognosis: a propensity score matched analysis from the AHEAD registry

Autoři

MIKLÍKOVÁ, Marie (203 Česká republika, garant, domácí), Jiří JARKOVSKÝ (203 Česká republika, domácí), Klára BENEŠOVÁ (203 Česká republika, domácí), Roman MIKLÍK (203 Česká republika, domácí), Marián FELŠŐCI (703 Slovensko, domácí), Jindřich ŠPINAR (203 Česká republika, domácí), Ladislav DUŠEK (203 Česká republika, domácí) a Jiří PAŘENICA (203 Česká republika, domácí)

Vydání

Congress of the European-Society-of-Cardiology (ESC) / World Congress of Cardiology, 2019

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30201 Cardiac and Cardiovascular systems

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 22.673

Kód RIV

RIV/00216224:14110/19:00113616

Organizační jednotka

Lékařská fakulta

ISSN

UT WoS

000507313000919

Klíčová slova anglicky

Hyperuricaemia treatment; acute heart failure; AHEAD registry

Štítky

rivok

Příznaky

Mezinárodní význam

Změněno: 14. 4. 2020 09:48, Mgr. Tereza Miškechová

Anotace

V originále

Background Hyperuricaemia is associated with a poorer prognosis in heart failure (HF) patients. Benefits of hyperuricaemia treatment with allopurinol have not yet been confirmed in clinical practice. The aim of our work was to assess the benefit of allopurinol treatment in a large cohort of HF patients. Methods and results The prospective acute heart failure registry (AHEAD) was used to select 3,160 hospitalized patients with a known level of uric acid (UA) who were discharged in a stable condition. Hyperuricaemia was defined as UA _>500mmol/l and/or allopurinol treatment at admission. The patients were classified into three groups: without hyperuricaemia, with treated hyperuricaemia and with untreated hyperuricaemia at discharge. Two- and five-year all-cause mortality were defined as endpoints. Patients without hyperuricaemia, unlike those with hyperuricaemia, had a higher left ventricular ejection fraction, a better renal function and higher haemoglobin levels, had less frequently diabetes mellitus and atrial fibrillation, and showed better tolerance to treatment with ACEIs/ARBs and/or beta-blockers. In a primary analysis, the patients without hyperuricaemia had the highest survival rate. After using the propensity score to set up comparable groups, the patients without hyperuricaemia had a similar five-year survival rate as those with untreated hyperuricaemia (42.0% vs 39.7%, p=0.362) whereas those with treated hyperuricaemia had a poorer prognosis (32.4% survival rate; p=0.006 vs non-hyperuricaemia group and p=0.073 vs untreated group). Conclusion Hyperuricaemia was associated with an unfavourable cardiovascular risk profile in HF patients. Treatment of hyperuricaemia with low doses of allopurinol did not improve the longterm prognosis of HF patients.

Návaznosti

MUNI/A/1250/2017, interní kód MU

Název: Validace Rule-out/rule-in protokolu u pacientů s bolestí na hrudi – pokračování v prospektivní studii

Investor: Masarykova univerzita, Validace Rule-out/rule-in protokolu u pacientů s bolestí na hrudi – pokračování v prospektivní studii, DO R. 2020_Kategorie A - Specifický výzkum - Studentské výzkumné projekty

Citovat

MIKLÍKOVÁ, Marie, Jiří JARKOVSKÝ, Klára BENEŠOVÁ, Roman MIKLÍK, Marián FELŠŐCI, Jindřich ŠPINAR, Ladislav DUŠEK a Jiří PAŘENICA. Hyperuricaemia treatment in acute heart failure patients does not improve their long-term prognosis: a propensity score matched analysis from the AHEAD registry. In Congress of the European-Society-of-Cardiology (ESC) / World Congress of Cardiology. 2019. ISSN 0195-668X.

@proceedings{1644938,
   author = {Miklíková, Marie and Jarkovský, Jiří and Benešová, Klára and Miklík, Roman and Felšőci, Marián and Špinar, Jindřich and Dušek, Ladislav and Pařenica, Jiří},
   booktitle = {Congress of the European-Society-of-Cardiology (ESC) / World Congress of Cardiology},
   keywords = {Hyperuricaemia treatment; acute heart failure; AHEAD registry},
   language = {eng},
   title = {Hyperuricaemia treatment in acute heart failure patients does not improve their long-term prognosis: a propensity score matched analysis from the AHEAD registry},
   url = {https://academic.oup.com/eurheartj/article-abstract/40/Supplement_1/ehz748.0415/5596975?redirectedFrom=fulltext},
   year = {2019}
}

TY  - CONF
ID  - 1644938
AU  - Miklíková, Marie - Jarkovský, Jiří - Benešová, Klára - Miklík, Roman - Felšőci, Marián - Špinar, Jindřich - Dušek, Ladislav - Pařenica, Jiří
PY  - 2019
TI  - Hyperuricaemia treatment in acute heart failure patients does not improve their long-term prognosis: a propensity score matched analysis from the AHEAD registry
KW  - Hyperuricaemia treatment
KW  - acute heart failure
KW  - AHEAD registry
UR  - https://academic.oup.com/eurheartj/article-abstract/40/Supplement_1/ehz748.0415/5596975?redirectedFrom=fulltext
L2  - https://academic.oup.com/eurheartj/article-abstract/40/Supplement_1/ehz748.0415/5596975?redirectedFrom=fulltext
N2  - Background Hyperuricaemia is associated with a poorer prognosis in heart failure (HF) patients. Benefits of hyperuricaemia treatment with allopurinol have not yet been confirmed in clinical practice. The aim of our work was to assess the benefit of allopurinol treatment in a large cohort of HF patients. Methods and results The prospective acute heart failure registry (AHEAD) was used to select 3,160 hospitalized patients with a known level of uric acid (UA) who were discharged in a stable condition. Hyperuricaemia was defined as UA _>500mmol/l and/or allopurinol treatment at admission. The patients were classified into three groups: without hyperuricaemia, with treated hyperuricaemia and with untreated hyperuricaemia at discharge. Two- and five-year all-cause mortality were defined as endpoints. Patients without hyperuricaemia, unlike those with hyperuricaemia, had a higher left ventricular ejection fraction, a better renal function and higher haemoglobin levels, had less frequently diabetes mellitus and atrial fibrillation, and showed better tolerance to treatment with ACEIs/ARBs and/or beta-blockers. In a primary analysis, the patients without hyperuricaemia had the highest survival rate. After using the propensity score to set up comparable groups, the patients without hyperuricaemia had a similar five-year survival rate as those with untreated hyperuricaemia (42.0% vs 39.7%, p=0.362) whereas those with treated hyperuricaemia had a poorer prognosis (32.4% survival rate; p=0.006 vs non-hyperuricaemia group and p=0.073 vs untreated group). Conclusion Hyperuricaemia was associated with an unfavourable cardiovascular risk profile in HF patients. Treatment of hyperuricaemia with low doses of allopurinol did not improve the longterm prognosis of HF patients.
ER  -

MIKLÍKOVÁ, Marie, Jiří JARKOVSKÝ, Klára BENEŠOVÁ, Roman MIKLÍK, Marián FELŠ$\backslash$H OCI, Jindřich ŠPINAR, Ladislav DUŠEK a Jiří PAŘENICA. Hyperuricaemia treatment in acute heart failure patients does not improve their long-term prognosis: a propensity score matched analysis from the AHEAD registry. In \textit{Congress of the European-Society-of-Cardiology (ESC) / World Congress of Cardiology}. 2019. ISSN~0195-668X.

Podrobný výpis o publikaci